Spectrum Pharmaceuticals Lawsuit (SPPI Lawsuit)
An SPPI class action lawsuit (Spectrum Pharmaceuticals Class Action Lawsuit) has been filed on behalf of investors who purchased Spectrum Pharmaceuticals Class Action Lawsuit (SPPI) securities between December 6, 2021 – September 22, 2022, inclusive. For more on the SPPI Lawsuit please contact us today.
According to the Spectrum Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
Defendants were conducting a phase 2 clinical trial called ZENITH20.
The ZENITH20 trial was an ongoing, multicenter, multi-cohort, open-label, activity-estimating study evaluating the anti-tumor effects, safety, and tolerability of poziotinib, or “pozi”, in patients with locally advanced or metastatic non small cell lung cancer (“NSCLC”) that have certain mutations (HER2 exon 20 insertion mutations) and were previously treated with the standard of care.
The Complaint further alleges that during the class period, Defendants represented the safety and efficacy data from the ZENITH20 trial were positive and that they had initiated a required confirmatory phase 3 study.
However, unknown to investors, this was not true.
If you suffered a loss in SPPI, you have until February 3, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Spectrum Pharmaceuticals Lawsuit,
Spectrum Pharmaceuticals Class Action Lawsuit,
Spectrum Pharmaceuticals Class Action,
SPPI Class Action Lawsuit,
SPPI Class Action,
SPPI Lawsuit,
SPPI Stock
